Status:

COMPLETED

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Lead Sponsor:

Celgene

Conditions:

Crohn Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Eligibility Criteria

Inclusion

  • For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com
  • Crohn's disease for ≥ 3 months on endoscopy and on histological exam
  • Inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy
  • Crohn's Disease Activity Index (CDAI) score ≥ 220 and ≤ 450
  • Average daily stool frequency ≥ 4 points and/or an abdominal pain of ≥ 2 points
  • Simple Endoscopic Score for Crohn's Disease (SES-CD) score of ≥ 6 (or SES-CD ≥ 4 in participants with isolated ileal disease)

Exclusion

  • Diagnosis of ulcerative colitis, indeterminate colitis, radiation colitis, or ischemic colitis, or has strictures with prestenotic dilatation requiring procedural intervention
  • Extensive small bowel resection (\>100cm) or known diagnosis of short bowel syndrome, or requires total parenteral nutrition
  • Current stoma, ileal-anal pouch anastomosis, or fistula
  • Other protocol-defined inclusion/exclusion criteria apply

Key Trial Info

Start Date :

March 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 21 2023

Estimated Enrollment :

606 Patients enrolled

Trial Details

Trial ID

NCT03440385

Start Date

March 7 2018

End Date

November 21 2023

Last Update

December 5 2024

Active Locations (368)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 92 (368 locations)

1

Local Institution - 202

Scottsdale, Arizona, United States, 85258

2

Ucsd Medical Center

La Jolla, California, United States, 92037

3

Local Institution - 010

Lancaster, California, United States, 93534

4

Southern California Research Institute Medical Group, Inc.

Los Angeles, California, United States, 90045